All AstraZeneca articles – Page 2
-
BusinessAstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
-
BusinessHow do chemical firms last hundreds of years?
What distinguishes companies that thrive from others that failed?
-
BusinessExpanding precision medicine beyond cancer
Exclusive interview with Koustubh Ranade, vice president of R&D at MedImmune
-
CareersCatching up with AstraZeneca's graduate programme
Three years on, Manisha Lalloo revisits the pharma giant’s training scheme
-
BusinessAstraZeneca sheds multiple drugs
Spate of licensing deals for non-core products as firm further tightens R&D focus
-
NewsPharma giants commit to tackling antimicrobial resistance
Plan to tackle superbugs includes changes to manufacturing and sales incentives
-
BusinessPfizer to buy Astrazeneca’s antibiotics
Deal tops up Pfizer’s late-stage development pipeline, but AZ will retain biological programmes
-
BusinessStandard antibody will bolster biopharma
New NIST reference material will help validate and compare analytical techniques
-
BusinessUnpicking doctor payments
Accepting even small meals from drug industry reps appears to influence doctors’ prescription rates
-
BusinessAstraZeneca licenses skin drugs to Leo
Offloading psoriasis and dermatitis antibodies continues AZ’s plan to refocus on fewer therapy areas
-
BusinessCrispr goes commercial
Gene editing technique Crispr has shaken up genomics research and the commercial opportunities couldn’t be more evident
-
BusinessFixing the broken antibiotics business model
With rising resistance and doomsday warnings, focus is turning to alternative economic models to boost antibiotic R&D
-
Business
AstraZeneca to buy Acerta for blood cancer drug
Deal will strengthen AstraZeneca’s immunotherapy offering
-
Business
Heptares takes on new partners for drug discovery
Firm set to receive over $1bn from research partnerships
-
Business
Drug firms to share chemical compound libraries
AstraZeneca and Sanofi aim to facilitate drug discovery by swapping 210,000 proprietary chemical compounds
-
Business
AstraZeneca to buy ZS Pharma for ion-balance drugs
$2.7 billion deal anticipates regulatory success for drug candidate under review
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
AstraZeneca sells off drugs to streamline portfolio
Crohn’s disease and rare thyroid cancer drugs lie outside firm’s renewed strategic focus
-
FeaturePharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page